Interferon beta in secondary progressive multiple sclerosis: Daily clinical practice

Journal of Neurology

Volumn 254, Issue 7, 2007, Pages 849-853

  Rio J ^a   Tintore M ^a   Nos, C ^a   Tellez N ^a   Galan I ^a   Pelayo, R ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Interferon beta; Multiple sclerosis; Observational study

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATALITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HERPES ZOSTER; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; SEPSIS; SIDE EFFECT;

ADULT; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; OBSERVATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34547673047     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0477-4     Document Type: Article

References (14)

1. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 46:907-911
2. Kappos L (2004) Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 10(Suppl 1):S46-54
3. Keegan BM, Noseworthy JH (2002) Multiple sclerosis. Annu Rev Med 53:285-302
4. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak, EL, et al. (2001) Immunopathology of secondary- progressive multiple sclerosis. Ann Neurol 50:646-657
5. European Study Group on interferon β-1b in secondary progressive MS. Placebo- controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis (1998) European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352(9139):1491-1497
6. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta- 1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56:1496-1504
7. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-687
8. The North American Study Group on interferon β-1b in secondary progressive MS (2004) Interferon beta-1b in secondary progressive MS. Neurology 63:1788-1795
9. Wingerchuk DM, Noseworthy JH (2002) Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 58(8 Suppl 4):S40-48
10. Weinshenker BG, Issa M, Baskerville J (1996) Meta-analysis of the placebotreated groups in clinical trials of progressive MS. Neurology 46:1613-1619
11. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al. (2004) Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63:1779-1787
12. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
13. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ, et al. (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11:306-309
14. Weinshenker BG, Issa M, Baskerville J (1996) Long-term and short-term outcome of multiple sclerosis. A 3-year follow-up study. Arch Neurol 53:353- 358